Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.antiviral.2012.07.008
Title: Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial
Authors: Watanabe, S.
Rathore, A.P.S. 
Sung, C.
Lu, F.
Khoo, Y.M.
Connolly, J.
Low, J.
Ooi, E.E.
Lee, H.S.
Vasudevan, S.G. 
Keywords: AG129 lethal infection mouse model
Antiviral
Dengue virus
Pharmacokinetics
Issue Date: Oct-2012
Citation: Watanabe, S., Rathore, A.P.S., Sung, C., Lu, F., Khoo, Y.M., Connolly, J., Low, J., Ooi, E.E., Lee, H.S., Vasudevan, S.G. (2012-10). Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Research 96 (1) : 32-35. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2012.07.008
Abstract: Celgosivir (6-O-butanoyl castanospermine), a pro-drug of the naturally occurring castanospermine, is an inhibitor of α-glucosidase I and II that is found to be a potent inhibitor of several enveloped viruses including all four serotypes of dengue virus. We showed previously that the compound fully protected AG129 mice from lethal infection with a mouse adapted dengue virus at a dose of 50. mg/kg twice daily (BID) for 5. days and was effective even after 48. h delayed treatment. Here we show that the protection by celgosivir is dose- and schedule-dependent and that a twice-a-day regimen of 50, 25 or 10. mg/kg is more protective than a single daily dose of 100. mg/kg. Treatment with 50. mg/kg BID castanospermine had comparable efficacy as 25. mg/kg BID celgosivir, suggesting that celgosivir is approximately twice as potent as castanospermine with respect to in vivo antiviral efficacy. Pharmacokinetics (PK) studies of celgosivir in mice showed that it rapidly metabolized to castanospermine. Simulation of the PK data with the survival data for the various doses of celgosivir tested suggests that the steady-state minimum concentration is a critical parameter to note in choosing dose and schedule. These results influenced the selection of the dose regimen for a proof-of-concept clinical trial of celgosivir as a treatment against dengue fever. © 2012 Elsevier B.V.
Source Title: Antiviral Research
URI: http://scholarbank.nus.edu.sg/handle/10635/110037
ISSN: 01663542
DOI: 10.1016/j.antiviral.2012.07.008
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

59
checked on Dec 11, 2018

WEB OF SCIENCETM
Citations

62
checked on Dec 11, 2018

Page view(s)

43
checked on Nov 9, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.